Loading...
Market
What will be the market share of Eftilagimod Alpha and Pembrolizumab in first-line treatment of PD-L1-negative HNSCC by December 31, 2024?
2
Resolution / Starting Odds
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Market analysis reports from healthcare and pharmaceutical industry analysts
Story
Immutep Reports Positive Results in PD-L1-Negative Head and Neck Cancer with Eftilagimod Alpha and Pembrolizumab
Jul 12, 2024, 01:54 PM
Immutep has reported positive results in first-line treatment of head and neck squamous cell carcinoma (HNSCC) patients with negative PD-L1 expression. The results were achieved using a combination of Eftilagimod Alpha and Pembrolizumab, which generated a favorable overall response rate (ORR). This announcement has led to an 18.4% pre-market increase in Immutep's stock price ($IMMP). The findings were highlighted during the ESMO Virtual Plenary and have been met with significant interest in the oncology community. The results were reported by SI.
View original story
Similar markets
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%